Bring the potential of ROZLYTREK® to life
ROZLYTREK demonstrates clinically meaningful and durable responses in NTRK fusion+ solid tumours and ROS1+ NSCLC, irrespective of baseline CNS metastases1
ROZLYTREK is a tyrosine kinase inhibitor with a well-tolerated and consistent safety profile in both adult and paediatric patients1,2
Therapeutic indications1
ROZLYTREK as monotherapy is indicated for the treatment of adult and paediatric patients 12 years of age and older, with solid tumours, expressing a NTRK gene fusion:
• who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and
• who have not received a prior NTRK inhibitor,
• who have no satisfactory treatment options.
ROZLYTREK as monotherapy is indicated for the treatment of adult patients with ROS1-positive, advanced NSCLC not previously treated with ROS1 inhibitors.
What is ROZLYTREK?
Discover ROZLYTREK
mode of action
ROS1+ NSCLC
Learn more about clinical
trials and efficacy
NTRK fusion+ solid tumours
Learn more about clinical trials
and efficacy
ROZLYTREK safety overview
Find out about
ROZLYTREK safety
Prescribing ROZLYTREK
ROZLYTREK offers convenient
once-daily dosing
Patient benefits
Find out how ROZLYTREK
helps patients
Gene fusion detection
Learn more about actionable
fusions and how to
identify them
Disease support
Help patients understand ROS1 and
NTRK fusion+ cancer
Coming soon
This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 of the SmPC for details on how to report adverse reactions.
Footnotes
CNS, central nervous system; NSCLC, non-small cell lung cancer; NTRK, neurotrophic tyrosine receptor kinase ROS1, c-ros oncogene ; SmPC, summary of product characteristics; TRK, tyrosine kinase.
References
We aim to get in touch within one business day
Disclaimer: I consent to my data being processed for the purpose of responding to my inquiry and in accordance with the Roche Global Privacy Policy & Privacy Notice for Pharmacovigilance